Incidence of psoriatic arthritis increases with increasing severity of psoriasis stratified by treatment severity surrogates

Risk increased for both persistent and placental infection and for both spontaneous and all preterm births

Compared with placebo, pembrolizumab prolonged regression-free survival in resected high-risk stage IIB and IIC melanoma

Despite 79.9 percent increase in parent-reported safety concerns, there was a drop in HPV vaccine-related reported adverse reactions

Sirolimus does not impact volume changes detected on MRI scans, but does reduce pain, oozing, bleeding

Individuals with rosacea have decrease in richness, evenness of the facial cutaneous microbiome and drop in abundance of

Patients with acne prescribed isotretinoin less likely to engage in suicidal behavior than those treated with antibiotics only or those in the general population

Reimbursement varied by procedure types, with increases for skin biopsy and shave removal, decreases for Mohs micrographic surgery

to be fixed

Exposure to positive household members linked to increased risk for infection for vaccinated health care workers

Adults receiving the vaccine between December 2020 and March 2021 reported decreased mental distress following first dose

Estimated tumor diameter increase in one year 4.46 mm for those with at least an infiltrative/micronodular component

Data show no increased risk for SSTIs with biologic agent use, but risk increased for biologic therapy with concomitant corticosteroid use

Including patient-reported outcome measures in routine care may facilitate individualized treatment for psoriasis

After adjustment for confounders, psoriasis may be linked to lower risk for developing dementia

Slight decrease seen from 2019, but difference was not significant; 13.9 percent of adults and 5.1 percent of children uninsured in 2020

Compared with infected unvaccinated individuals, infected vaccinated individuals report almost all symptoms less frequently

In 2020, lower-than-expected proportion of melanomas diagnosed at stages 0 to IA; higher-than-expected percent diagnosed at stages IIC, III, IV

Most efficacious treatment achieved with ligelizumab 72 or 240 mg and omalizumab 300 or 600 mg for chronic spontaneous urticaria

Mild-to-moderate atopic dermatitis not linked to symptoms of depression, but linked to internalizing behaviors from age 4 years

For five of six actinic damage and skin cancer index stages, consensus-based recommendations developed